Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, H1 2017’, provides in depth analysis on Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease under development targeting Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

– The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics and enlists all their major and minor projects

– The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Crescendo Biologics Ltd

Enumeral Biomedical Holdings Inc

GlaxoSmithKline Plc

Icell Kealex Therapeutics

Incyte Corp

MacroGenics Inc

Merck & Co Inc

Novartis AG

Prima BioMed Ltd

Regeneron Pharmaceuticals Inc

Sutro Biopharma Inc

Symphogen A/S

Tesaro Inc

Trellis Bioscience Inc

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Crescendo Biologics Ltd

Enumeral Biomedical Holdings Inc

GlaxoSmithKline Plc

Icell Kealex Therapeutics

Incyte Corp

MacroGenics Inc

Merck & Co Inc

Novartis AG

Prima BioMed Ltd

Regeneron Pharmaceuticals Inc

Sutro Biopharma Inc

Symphogen A/S

Tesaro Inc

Trellis Bioscience Inc

Xencor Inc

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles

BI-754111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENUM-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IKT-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAG-525 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGD-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4280 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2810 + REGN-3767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRL-7117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-033 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones

Featured News & Press Releases

May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

Jan 03, 2017: Prima Announces New Product Candidate IMP761 - A LAG-3 Agonist Antibody

Aug 25, 2016: European Patent Grants for IMP731 Antibody

Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016

Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates

Jan 27, 2016: US Patent Grants for IMP731 Antibody

Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program

May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Boehringer Ingelheim GmbH, H1 2017

Pipeline by Bristol-Myers Squibb Company, H1 2017

Pipeline by Crescendo Biologics Ltd, H1 2017

Pipeline by Enumeral Biomedical Holdings Inc, H1 2017

Pipeline by GlaxoSmithKline Plc, H1 2017

Pipeline by Icell Kealex Therapeutics, H1 2017

Pipeline by Incyte Corp, H1 2017

Pipeline by MacroGenics Inc, H1 2017

Pipeline by Merck & Co Inc, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Prima BioMed Ltd, H1 2017

Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Pipeline by Sutro Biopharma Inc, H1 2017

Pipeline by Symphogen A/S, H1 2017

Pipeline by Tesaro Inc, H1 2017

Pipeline by Trellis Bioscience Inc, H1 2017

Pipeline by Xencor Inc, H1 2017

Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports